Get the Stockscreener App
28.06
1.72%
-0.49
After Hours:
28.19
0.13
+0.46%
Roivant Sciences Ltd stock is traded at $28.06, with a volume of 5.45M.
It is down -1.72% in the last 24 hours and up +6.09% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$28.55
Open:
$28.87
24h Volume:
5.45M
Relative Volume:
0.78
Market Cap:
$20.08B
Revenue:
$125.68M
Net Income/Loss:
$4.81B
P/E Ratio:
4.9664
EPS:
5.65
Net Cash Flow:
$-781.21M
1W Performance:
-2.50%
1M Performance:
+6.09%
6M Performance:
+99.29%
1Y Performance:
+169.29%
1-Day Range:
$27.92
$29.23
1-Week Range:
$27.92
$30.33
52-Week Range:
$8.73
$30.33
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
28.06 | 20.43B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Roivant Sciences Hits New 52-Week High at $30.30, Up 180.72% - Markets Mojo
Roivant Sciences stock hits all-time high at 30.31 USD - Investing.com India
Roivant at Leerink Conference: Strategic Transformation Insights - Investing.com Australia
Dimensional Fund Advisors LP Has $140.84 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences (NASDAQ:ROIV) Reaches New 52-Week HighHere's Why - MarketBeat
(ROIV) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Roivant Sciences stock hits all-time high at 29.23 USD - Investing.com Nigeria
WINTON GROUP Ltd Purchases 335,269 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Aug Rallies: Can Roivant Sciences Ltd. sustain earnings growthQuarterly Portfolio Report & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Roivant Sciences Hits New 52-Week High at $29.20, Up 170.89% - Markets Mojo
Dow Update: Can Roivant Sciences Ltd outperform under higher oil pricesJuly 2025 Intraday Action & Weekly High Return Forecasts - baoquankhu1.vn
Neo Ivy Capital Management Has $3.59 Million Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Blue Owl Capital Holdings LP Acquires New Holdings in Roivant Sciences Ltd. $ROIV - MarketBeat
Sentiment Review: Is Roivant Sciences Ltd stock undervalued right nowGap Up & Low Risk High Reward Ideas - baoquankhu1.vn
Roivant Sciences Ltd. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
HC Wainwright Expects Stronger Earnings for Roivant Sciences - MarketBeat
9 Biotech Stocks Trading Far Below Fair Value With Up to 250% Upside Potential - Investing.com
Roivant Sciences Hits New 52-Week High at $29.82, Up 179% - Markets Mojo
Roivant Sciences Hits Day High with Strong 6% Intraday Surge - Markets Mojo
Roivant Sciences stock hits all-time high at 29.23 USD By Investing.com - Investing.com Canada
Cowen Maintains Buy on Roivant Sciences Ltd (ROIV) March 2026 - Meyka
H.C. Wainwright raises Roivant Sciences stock price target to $34 on settlement proceeds By Investing.com - Investing.com South Africa
A Look At Roivant Sciences (ROIV) Valuation After Recent Share Price Strength - Yahoo Finance
Key facts: Roivant Sciences secures $2.25B settlement; boosts buyback to $1B; price target raised to $34 - TradingView
Moderna to pay up to $2.25B to settle COVID-19 patents case - BioWorld MedTech
Roivant Sciences (NASDAQ:ROIV) Reaches New 12-Month High After Analyst Upgrade - MarketBeat
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS - TradingView
TD Cowen reiterates Roivant Sciences stock rating on drug launch timing By Investing.com - Investing.com South Africa
Moderna gains as Arbutus/ Genevant settlement removes major financial risk - Seeking Alpha
Roivant Sciences (NASDAQ:ROIV) Price Target Raised to $34.00 at HC Wainwright - MarketBeat
Roivant Sciences Ltd. $ROIV Shares Purchased by TD Asset Management Inc - MarketBeat
A Glimpse Into The Expert Outlook On Roivant Sciences Through 7 Analysts - Benzinga
H.C. Wainwright raises Roivant Sciences stock price target to $34 on settlement proceeds - Investing.com Australia
What Roivant Sciences (ROIV)'s Priority FDA Review for Brepocitinib in Dermatomyositis Means For Shareholders - Yahoo Finance
Wolfe Research reiterates Roivant Sciences stock rating at Outperform By Investing.com - Investing.com Australia
The Bull Case For Roivant Sciences (ROIV) Could Change Following Brepocitinib’s Priority Review In Dermatomyositis - simplywall.st
Jefferies Maintains Buy on Roivant Sciences Ltd. (ROIV) March 2026 - Meyka
ROIV: $2.25B settlement with Moderna resolves all LNP patent disputes and enables major share repurchase - TradingView
Roivant Sciences Ltd. (ROIV) announced that its board of directors has officially approved a stock buyback plan totaling up to 1 billion dollars. - Bitget
Vertiv (Vertiv Holdings LLC) recently announced the successful completion of two key financing transactions: a $2.1 billion senior unsecured bond issuance and a $2.5 billion senior unsecured revolving credit facility. - Bitget
Roivant, Arbutus Biopharma stocks surges on $2.25B Moderna settlement By Investing.com - Investing.com Australia
Roivant Subsidiaries Genevant and Arbutus Reach $2.25 Billion Settlement with Moderna Over Patent Infringement - Quiver Quantitative
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna - marketscreener.com
Roivant unit lands up to $2.25B in Moderna COVID vaccine patent deal - Stock Titan
Jefferies reiterates Roivant Sciences stock rating on pipeline progress - Investing.com Nigeria
Jefferies reiterates Roivant Sciences stock rating on pipeline progress By Investing.com - Investing.com South Africa
The biopharmaceutical company Arbutus Biopharma Corporation (ABUS), a subsidiary of Roivant Sciences Ltd. (ROIV), is currently actively evaluating a capital return plan. - Bitget
Roivant Sciences receives FDA priority review for dermatomyositis drug By Investing.com - Investing.com Australia
Roivant's Priovant Says FDA Accepts Application With Priority Review for Dermatomyositis Treatment - marketscreener.com
Roivant Sciences receives FDA priority review for dermatomyositis drug - Investing.com
Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis - GlobeNewswire
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):